Open letter to Sanofi: Reduce rifapentine cost and increase research funding

Leading doctors, advocacy groups, medical organizations and U.S. TB programs call upon Sanofi to lower the price of rifapentine to ensure its accessibility and continue and expand its investments in the development of the drug for active TB.

"The millions of people worldwide with TB (including nearly 10,000 people in the U.S. alone, and their hundreds of thousands of infected contacts) need better treatment options urgently. And care providers, TB programs and taxpayers urgently need these to be affordable, now. Sanofi, we ask you to take a stand and demonstrate your commitment to rifapentine development and access by:

1. Lowering the price of rifapentine to $35 per box of 32 tablets of 150 mg; and
2. Pledging $2 million to the TBTC for the continued development of rifapentine."

You can download the letter from here.

Comments in chronological order

Germaine Jacquette, MD wrote on July 4, 2013, 4:03 a.m.

INH & Rifapentine combined therapy for latent TB infection has been well received by patients in the year we have been offering this regimen. The excellent adherence shown may translate into improved efficacy in preventing active disease, but the high cost could put some drag on the drive for offering more patients the rifapentine-containing regimen. Sanofi has the opportunity to help in the fight against TB by lowering the price of Rifapentine.

To subscribe to the Weekly Newsletter of new posts, enter your email here:

By Treatment Action Group

Published: July 3, 2013, 10:34 a.m.

Last updated: July 3, 2013, 11:14 a.m.

Tags: None

Print Share